

Performance Against Delivery Benchmark

Count	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure
1	17/NE/0117	222778	Osteogenesis Imperfecta 3082/0003 Mereo BioPharma	Number Agreed	1	1	Date Agreed	30/12/2018	4	05/10/2018	4	Recruitment Finished
2	15/NE/0167	171524	MLN9708 in Multiple Myeloma Not Treated with Stem Cell transplantation - MILLENIUM	Number Agreed	4	4	Date Agreed	31/10/2018	3	08/10/2018	3	Recruitment Finished
3	16/LO/0581	194313	CANC 5246	Number Agreed	1	1	Date Agreed	15/10/2018	2	11/10/2018	2	Recruitment Finished
4	14/SC/1366	135118	NCRN - 3131: EPOCH TheraSphere in Metastatic Colorectal Carcinoma of the Liver (TS102)	Number Agreed	3	3	Date Agreed	30/09/2018	3	26/10/2018	3	Recruitment Finished
5	18/NW/0015	233850	CONSTANT	Number Agreed	50	50	Date Agreed	28/09/2018	62	31/10/2018	65	Recruitment Finished
6	17/LO/1656	229212	CO39722 - Cobimetinib and atezolizumab v's pembrolizumab in melanoma	Number Agreed	3	3	Date Agreed	31/10/2018	2	07/11/2018	2	Recruitment Finished
7	18/EM/0027	235145	OPT-302 with ranibizumab for the treatment of wet AMD	Number Agreed	2	2	Date Agreed	30/11/2018	0	14/11/2018	0	Recruitment Finished
8	17/SW/0273	235783	SB11-G31-AMD-Comparison of efficacy&safety of SB11 and Lucentis in AMD	Number Agreed	5	5	Date Agreed	30/11/2018	5	14/11/2018	5	Recruitment Finished
9	18/LO/0683	239811	YO40245 (IMBrave150) - Atezolizumab & Bevacizumab Vs. Sorafenib in HCC	Number Agreed	4	4	Date Agreed	30/06/2021	0	08/12/2018	0	Recruitment Finished
10	15/NW/0009	160002	MCRN3127 (20130173)	Number Agreed	3	3	Date Agreed	31/01/2019	5	13/12/2018	5	Recruitment Finished
11	17/EM/0063	213979	Gilteritinib as Maintenance After Induction/Consolidation in CR1 AML (Astellas AML Maintenance Study	Number Agreed	2	2	Date Agreed	30/11/2018	0	15/10/2018	0	Withdrawn by Host
12	18/LO/0126	239586	Phase 1 study of WVE-210201 in patients with DMD	Number Agreed	1	1	Date Agreed	21/12/2018	1	20/12/2018	1	Recruitment Finished
13	17/EM/0355	229043	SPIRIT 2 #	Number Agreed	4	4	Date Agreed	28/02/2019	0	28/02/2019	0	Withdrawn by Host
14	17/EE/0437	233853	AQUILA (54767414SMM3001)	Number Agreed	2	2	Date Agreed	13/12/2019	4	07/03/2019	4	Recruitment Finished
15	18/EM/0228	248988	Anti-viral effect of PC786 on RSV infection in HSCT recipients	Number Agreed	3	3	Date Agreed	11/03/2019	2	11/03/2019	2	Recruitment Finished
16	18/LO/0378	234232	PIONEER III	Number Agreed	12	12	Date Agreed	30/06/2019	6	15/03/2019	6	Recruitment Finished
17	17/SC/0228	219158	Javelin Head and Neck	Number Agreed	4	4	Date Agreed	08/04/2021	3	18/12/2018	3	Recruitment Finished
18	18/SW/0050	235126	A3921288 Phase 3B/4 Study of Tofacitinib in Subjects with UC	Number Agreed	1	1	Date Agreed	30/04/2019	1	02/04/2019	1	Recruitment Finished
19	17/NI/0096	225743	HOPE-1	Number Agreed	3	3	Date Agreed	30/04/2019	3	29/04/2019	3	Recruitment Finished
20	14/LO/0566	145475	CANC - 3490 OLYMPIA	Number Agreed	3	3	Date Agreed	30/04/2019	30	30/04/2019	30	Recruitment Finished
21	17/EE/0474	229785	AdAPT: Adenovirus after Allogeneic Paediatric Transplantation	Number Agreed	2	2	Date Agreed	31/05/2019	1	13/05/2019	1	Recruitment Finished
22	17/SW/0221	232448	(CAIN457K2340) Secukinumab compared with GP2017 in Active AS	Number Agreed	3	3	Date Agreed	30/06/2019	2	31/05/2019	2	Recruitment Finished
23	18/LO/1238	245332	Open Label Extension study of WVE-210201 in patients with DMD	Number Agreed	1	1	Date Agreed	30/06/2019	1	05/06/2019	1	Recruitment Finished
24	15/YH/0478	186697	HEPA - 5032 The REGENERATE Study	Number Agreed	2	2	Date Agreed	30/07/2019	3	17/06/2019	3	Recruitment Finished

Performance Against Delivery Benchmark

Count	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure
25	18/LO/1311	248599	GR40398 EFFICACY AND SAFETY OF RO6867461 IN DMO PATIENTS (RHINE) v1	Number Agreed	5	5	Date Agreed	30/11/2019	2	22/08/2019	2	Recruitment Finished
26	18/WS/0137	247036	VISION Study of 177Lu-PSMA-617 in the treatment of PSMA-Positive mCRPC	Number Agreed	6	6	Date Agreed	22/08/2019	3	29/08/2019	3	Recruitment Finished
27	19/EM/0003	251874	Phase 3 Study of Edasalonexent in Duchenne Muscular Dystrophy	Number Agreed	2	2	Date Agreed	30/06/2020	4	03/09/2019	4	Recruitment Finished
28	18/SC/0342	247085	Phase III Trial of AMT-061 in adults with haemophilia B	Number Agreed	1	1	Date Agreed	30/09/2019	0	03/09/2019	0	Recruitment Finished
29	18/WS/0172	251636	1011712	Number Agreed	5	5	Date Agreed	30/08/2019	0	04/09/2019	0	Withdrawn by Sponsor
30	16/LO/0543	198734	GMP Drink for PKU Study	Number Agreed	1	1	Date Agreed	31/12/2019	3	30/09/2019	3	Recruitment Finished